Abbott Laboratories $ABT Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 0.2% in the third quarter, Holdings Channel.com reports. The firm owned 173,154,308 shares of the healthcare product maker’s stock after acquiring an additional 353,457 shares during the period. Vanguard Group Inc. owned about 0.10% of Abbott Laboratories worth $23,192,288,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. IMG Wealth Management Inc. grew its stake in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after acquiring an additional 167 shares in the last quarter. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter valued at approximately $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories during the 3rd quarter worth approximately $31,000. Anfield Capital Management LLC raised its position in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares in the last quarter. Finally, Delos Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories during the 2nd quarter valued at approximately $32,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Royal Bank Of Canada cut their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Sanford C. Bernstein dropped their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Piper Sandler reduced their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Leerink Partners lowered their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Finally, Oppenheimer cut their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $112.63 on Monday. The company has a market cap of $195.84 billion, a PE ratio of 30.28, a P/E/G ratio of 1.79 and a beta of 0.75. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23. The firm has a 50-day simple moving average of $119.48 and a 200 day simple moving average of $126.39. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, February 13th. Shareholders of record on Thursday, January 15th were given a $0.63 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.